Trials / Completed
CompletedNCT00314054
Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCV-796 | HCV-796 1000mg single dose |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-04-12
- Last updated
- 2008-04-14
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00314054. Inclusion in this directory is not an endorsement.